Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

>> Preview...
In the News
Greg Scott presents industry update during JPMorgan
>> View video…

>> More News...

Now on Twitter!
 

Twitter ID: ChinaBio

Abbott Granted China Approval for Drug Eluting Stent

publication date: Sep 14, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Abbott Labs was given SFDA approval for its Xience V® drug eluting stent system as a treatment for coronary artery disease (CAD), the leading cause of death in China. The approval was based on two worldwide clinical trials that enrolled 1302 patients, including 60 patients from two sites in China. Abbott says it plans to launch the device in Q4. More details...

Stock Symbol: (NYSE: ABT)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events
April 14, 2010
Guangzhou, China

SEED Final Competion and Award Ceremony
April 23, 2010
Shanghai, China
Suzhou, China
June 23-24, 2010
 
Partner Events

China 2010 Pharmaceutical R&D Summit
Shanghai, China
April 5-8, 2010
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners